Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4296661 Target Snapshot

mTORC1 · PROTEIN COMPLEX · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
295Compounds
180Assays
2Approved Drugs
307.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

mTORC1 shows clinical signal disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P42345. Start with breast cancer, then reuse UniProt P42345 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with breast cancer, then reuse UniProt P42345 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
breast cancer

mTORC1 shows clinical signal disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with breast cancer because it currently carries clinical signal support. Linked drugs include INDOXIMOD. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats mTORC1 as ChEMBL target CHEMBL4296661, mapped to UniProt P42345. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
mTORC1
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4296661
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P42345
Serine/threonine-protein kinase mTOR
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether mTORC1 is the right protein anchor across sources, using UniProt P42345 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why breast cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NamemTORC1
Target TypePROTEIN COMPLEX
OrganismHomo sapiens
UniProtP42345
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase mTOR
UniProt AccessionP42345
Component TypeProtein
Sequence Length2549 aa

Serine/threonine-protein kinase mTOR

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as mTORC1, mapped to UniProt P42345. ChEMBL maps the protein component as Serine/threonine-protein kinase mTOR. Sequence length is 2549 aa.

Mapped IDP42345
Review namemTORC1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

mTORC1 shows clinical signal disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugINDOXIMOD
Clinical signal Phase II
melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugINDOXIMOD
Clinical signal Phase II
metastatic melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugINDOXIMOD
Clinical signal Phase II
metastatic prostate cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugINDOXIMOD
Clinical signal Phase I
acute myeloid leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugINDOXIMOD
Clinical signal Phase I
brain cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugINDOXIMOD
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with breast cancer because it currently carries clinical signal support. Linked drugs include INDOXIMOD. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebreast cancer
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase III
8
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50300.0
KI6.0
EC501.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5420034 10.7 IC50 0.02 Preclinical
CHEMBL5429186 10.52 IC50 0.03 Preclinical
CHEMBL5418335 10.4 IC50 0.04 Preclinical
CHEMBL1908360 10.3 IC50 0.05 Approved
CHEMBL413 10.3 IC50 0.05 Approved
CHEMBL5218737 10.0 IC50 0.1 Preclinical
CHEMBL5430111 9.89 IC50 0.13 Preclinical
CHEMBL5422529 9.85 IC50 0.14 Preclinical
CHEMBL5441038 9.85 IC50 0.14 Preclinical
CHEMBL5404497 9.8 IC50 0.16 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
8
5.5
23
6.0
28
6.5
51
7.0
25
7.5
41
8.0
17
8.5
30
9.0
23
9.5
pChEMBL
Approved Drugs

Approved Drugs

EVEROLIMUS
CHEMBL1908360
Approved 2009
Properties Compare Identifier
SIROLIMUS
CHEMBL413
Approved 1999
Properties Compare Identifier
Assay Landscape

Assay Landscape

180
Total Assays
219
Tested Compounds
1
Assay Types
Binding — 180 assays, 219 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 163 189 7.9
protein complex format 17 30 8.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine